ABSTRACT
BACKGROUND: This study assessed trends in treatment and outcomes of anal melanomas over a 17-year period. METHODS: NCDB was searched for patients with anal melanoma (2004-2020). Receiver-operating characteristic curve analysis was used to determine cutoff year marking increased overall survival (OS) of anal melanoma. Characteristics, treatments, and outcomes in consecutive time periods were compared. RESULTS: A total of 815 patients (mean age: 67.2 years; 59.4% female) were included: 354 in Period 1 (2004-2012) and 461 in Period 2 (2013-2020). Period 2 included fewer abdominoperineal resections (18% vs. 28%, p = 0.002), more local tumor excisions (61.1% vs. 55%, p = 0.002), more often immunotherapy (odds ratio [OR]: 3.41, 95% confidence interval [CI]: 2.22-5.22, p < 0.001) and less often chemotherapy (OR: 0.516, 95% CI: 0.352-0.755, p < 0.001) administered and longer median OS (25.2 vs. 19.8 months, p = 0.006). Independent predictors of worse OS were older age (hazard ratio [HR]: 1.02, p = 0.012), higher Charlson score (HR: 2.32, p = 0.02), and greater number of positive lymph nodes (HR: 1.15, p < 0.001); conversely private insurance (HR: 0.385, p = 0.008) was predictive of increased OS. CONCLUSIONS: Anal melanoma patients diagnosed between 2013 and 2020 underwent fewer abdominoperineal resections and more local excisions than patients diagnosed between 2004 and 2013. Increased immunotherapy and longer median OS were noted in period two. Age and private insurance were significant predictors of OS, remaining constant across time periods.
Subject(s)
Anus Neoplasms , Databases, Factual , Melanoma , Humans , Melanoma/surgery , Melanoma/mortality , Melanoma/pathology , Female , Male , Anus Neoplasms/surgery , Anus Neoplasms/mortality , Anus Neoplasms/pathology , Aged , Middle Aged , Survival Rate , Follow-Up Studies , Retrospective Studies , Prognosis , Aged, 80 and overABSTRACT
BACKGROUND: Anal melanoma is rare. Surgery is standard of care for non-metastatic disease. There are limited data supporting adjuvant therapy. We sought to examine the impact of adjuvant radiation, chemotherapy and immunotherapy on survival. METHODS: The National Cancer Database was queried. Factors associated with overall survival were examined by Kaplan-Meier and Cox proportional hazards analyses. Patients were grouped by treatment regimen. RESULTS: 450 patients had complete treatment data: surgery alone (63.8%), surgery + radiation (14.9%), surgery + chemotherapy (7.6%), surgery + immunotherapy (9.6%) and non-surgical treatment (4.2%). Median survival was 27.2 months. Node-positive patients had worse survival than node-negative (22.4 vs. 36.8 months; p = 0.0002). Non-surgical treatment yielded worse survival than any surgery-inclusive regimen (10.4 vs. 27.8 months; p = 0.0002). No adjuvant modality conferred a survival advantage. By multivariate analysis, increasing age (HR/1 year = 1.02, p = 0.012) and node positivity (HR = 2.10, p = 0.0002) negatively impacted survival. CONCLUSION: Adjuvant therapy for non-metastatic anal melanoma does not appear to influence survival.
Subject(s)
Anus Neoplasms , Melanoma , Skin Neoplasms , Anus Neoplasms/surgery , Chemotherapy, Adjuvant , Combined Modality Therapy , Humans , Kaplan-Meier Estimate , Melanoma/pathology , Melanoma/surgery , Neoplasm Staging , Proportional Hazards Models , Radiotherapy, Adjuvant , Retrospective Studies , Skin Neoplasms/pathologyABSTRACT
The aim of this report is to highlight the challenges involved in the diagnosis and treatment of anal melanoma in a tertiary hospital in Nigeria. It is a case report of an 84-year-old man who was managed for anal malignant melanoma. Despite inadequate investigative tools and less radical surgical treatment, the survival period of the index patient was comparable to the median survival quoted in the literature. Despite its rarity, mucosal melanomas also occur in the tropics. Prompt diagnosis, adequate imaging, and standardized treatment may improve its outlook in the nearest future.
ABSTRACT
PURPOSE: Anal mucosal melanoma is an uncommon malignancy of the anal canal, with few large studies available to establish clear trends in the treatment modalities presently available. The primary goal of this study was to identify the patterns of care in the treatment of anal melanoma and secondarily to determine outcomes. METHODS: This was a retrospective study performed utilizing the National Cancer Database (NCDB). A total of 787 patients diagnosed with anal melanoma between 2004 and 2014 were selected, of which 398 had staging information. The four treatment groups analyzed were surgical excision alone, surgical excision and radiation therapy, surgical excision and immunotherapy/chemotherapy, and radiation therapy plus minus immunotherapy/chemotherapy. Treatment was grouped by extent of disease; the Kaplan-Meier method was used to analyze overall survival and multivariate Cox proportional model was used to identify factors associated with overall survival. RESULTS: The majority of patients presented with either node-positive (39.4%) or metastatic disease (37.4%). Patients with surgical excision and radiation therapy had the highest median survival at 32.3 months. This is in contrast with those receiving surgical excision alone (22.9 months), surgery and immunotherapy/chemotherapy (18.4 months), and radiation without surgery (5.1 months) (p < 0.0001). CONCLUSIONS: Treatment with surgical excision was the most common initial treatment with no single modality superior over another in this rare entity.
Subject(s)
Anus Neoplasms/therapy , Melanoma/therapy , Skin Neoplasms/therapy , Anus Neoplasms/mortality , Anus Neoplasms/pathology , Female , Humans , Male , Melanoma/mortality , Melanoma/pathology , Retrospective Studies , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Survival Analysis , Treatment OutcomeABSTRACT
Anorectal melanoma is a rare and aggressive malignancy with a poor prognosis. Anorectal melanoma makes up approximately 1 to 3% of all anorectal malignancies. There are no known risk factors for anorectal melanoma. Patients frequently experience a delay in diagnosis due to multiple factors including nonspecific symptoms and misdiagnosis for other benign entities. Anorectal melanoma has a high potential for distant metastases and radiographic imaging plays a key role in evaluating for metastatic disease. Common sites for metastasis include pelvic lymph nodes, lungs, liver, skin, and brain. We present a case report of a 75 year old female with a history of transanal excision of primary anorectal melanoma who presented with increasing abdominal pain and distention. Computed tomography scan of the abdomen and pelvis showed metastatic disease to the peritoneum with findings of extensive peritoneal carcinomatosis, demonstrating the aggressive nature of anorectal melanoma.
Subject(s)
Anus Neoplasms/pathology , Melanoma/secondary , Peritoneal Neoplasms/secondary , Abdominal Pain/etiology , Aged , Diagnosis, Differential , Female , Humans , Magnetic Resonance Imaging , Melanoma/diagnostic imaging , Melanoma/pathology , Peritoneal Neoplasms/diagnostic imaging , Peritoneal Neoplasms/pathology , Positron Emission Tomography Computed Tomography , Radiography , Tomography, X-Ray Computed , UltrasonographyABSTRACT
AIM: In this study, we aimed to evaluate the clinical characteristics and outcomes of the patients with anal melanoma (AM), who underwent surgical treatment. MATERIALS AND METHODS: This study was conducted in Kartal Training and Research Hospital between January 2010 and December 2017. All patients, who underwent surgical resection with a diagnosis of AM, were enrolled. RESULTS: A total of 10 patients were examined, 8 of them were females, and their average age was 69.2 years (range, 47-85 years). Abdominoperineal resection (APR) was performed in five (50%) patients, and local excision (LE) was performed in other five (50%) patients. Three patients (30%) had stage I disease, two (20%) had stage II disease, and five (50%) had stage III disease. All five patients in APR group had stage III disease. In the comparison of the survival period after surgery, the mean survival period of the APR group was 6.2 months (range, 1-16 months) while that of the LE group was 19.6 months (range, 7-43 months). CONCLUSION: LE with adjuvant radiation seems to offer good locoregional control without reducing the survival and may be an option of treatment for patients with small, superficial AM. However, APR should be offered for patients with locally advanced disease or as a salvage following recurrence.
Subject(s)
Anus Neoplasms/surgery , Melanoma/surgery , Proctectomy/methods , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Rectal Neoplasms , Treatment OutcomeABSTRACT
The detection of primary anorectal melanoma on anal cytology is a rare and challenging diagnosis. We report a case where anorectal cytology showed isolated malignant cells with oval nuclei, prominent nucleoli, and elongated wispy cytoplasmic projections. There was no evidence of squamous dysplasia or melanin pigment identified. To the best of our knowledge, this is the first reported case of a primary anorectal melanoma detected in anorectal cytology. Detection of malignancies other than squamous cell carcinoma can be seen on anorectal cytology and should be considered when there is no evidence of anal intraepithelial neoplasia. Diagn. Cytopathol. 2017;45:452-455. © 2017 Wiley Periodicals, Inc.
Subject(s)
Anus Neoplasms/diagnosis , Biomarkers, Tumor/genetics , HIV Infections/diagnosis , Melanoma/diagnosis , Aged , Anal Canal/pathology , Anus Neoplasms/complications , Anus Neoplasms/genetics , Anus Neoplasms/pathology , HIV Infections/complications , HIV Infections/genetics , HIV Infections/pathology , Humans , Immunohistochemistry , MART-1 Antigen/genetics , Male , Melanoma/complications , Melanoma/genetics , Melanoma/pathology , S100 Proteins/geneticsABSTRACT
Uncommon neoplasms of the anal canal are associated with significant diagnostic dilemma in clinical practice and a high index of suspicion and pathologic expertise is needed. The incidence is likely to increase, particularly of small, incidental lesions found because of use of more frequent colonoscopy and high-definition MRI. Generally treatment follows that of the same histologic subtype in other anatomic location. Surgical intervention is the cornerstone for cure in early/localized disease; however, removal of the anal canal is associated with significant morbidities and quality of life issues. A centralized global registry/database established under the auspices of the International Rare Care Initiative collaboration would be useful.
Subject(s)
Anus Neoplasms/pathology , Lymphoma/pathology , Melanoma/pathology , Neuroendocrine Tumors/pathology , Humans , Incidence , Quality of LifeABSTRACT
BACKGROUND: Anorectal malignant melanomas (ARMM) are rare tumors, characterized by an early lymphatic spread and distant metastasis, resulting in an extremely poor overall survival. The objective of this study was to determine the pattern of regional lymph node metastasis (LNM) by computed tomography (CT) and 18F-FDG-PET/CT in patients undergoing abdominoperineal resection (APR) and its impact on oncologic outcome. METHODS: A retrospective analysis of six consecutive patients who underwent APR due to primary ARMM was performed. Patients were staged by CT and PET/CT. RESULTS: Four out of six patients had preoperative LNM involvement (two patients inguinal and perirectal, one iliacal, one perirectal), with two of them presenting with distant metastases additionally. Inguinal/iliacal LNM in two patients as well as liver metastasis in one patient was seen in PET/CT and missed by CT. The three patients with initial inguinal/iliacal LNM died during the observation period (overall survival: 10 (6-18) months). The three patients without inguinal/iliacal LNM involvement are currently alive, one patient showing a slowly progressive disease since 5 years, and two patients are tumor-free since 8.5 and 1.5 years (the patients had initial perirectal LNM). CONCLUSIONS: In ARMM, PET/CT is superior to CT in detection of LNM and distant metastasis. APR is possibly a curative approach if the PET/CT shows exclusively perirectal LNM despite locally advanced tumor growth.
Subject(s)
Anus Neoplasms/surgery , Fluorodeoxyglucose F18/administration & dosage , Lymph Nodes/pathology , Melanoma/surgery , Patient Selection , Positron Emission Tomography Computed Tomography/methods , Rectal Neoplasms/surgery , Aged , Anal Canal/surgery , Anus Neoplasms/diagnostic imaging , Anus Neoplasms/mortality , Colon, Sigmoid/surgery , Female , Humans , Lymph Nodes/diagnostic imaging , Lymphatic Metastasis , Male , Melanoma/diagnostic imaging , Melanoma/mortality , Middle Aged , Radiopharmaceuticals/administration & dosage , Rectal Neoplasms/diagnostic imaging , Rectal Neoplasms/mortality , Rectum/surgery , Retrospective Studies , Treatment OutcomeABSTRACT
AIM: Anal melanoma is a rare malignancy with a poor prognosis. METHOD: All patients with a diagnosis of anal melanoma treated at a single institution between 2000 and 2012 were identified and their treatment and outcome were evaluated. RESULTS: Sixteen patients had a median survival of 2.9 years. Fourteen had Stage I or II disease with a median survival of 4.0 years and progression-free survival of 1.5 years. When used for disease staging, whole body positron emission tomography/CT identified an additional three sites of metastasis in five patients compared with CT of the chest, abdomen and pelvis. Surgery involved wide local excision or abdominoperineal excision with respective local recurrence rates of 50% and 66%. Eleven patients underwent testing for c-Kit mutations, of whom five were positive. Four of these were treated with the tyrosine kinase inhibitor imatinib, and showed rapid response of metastases outside the central nervous system. CONCLUSION: The outcome of this malignancy remains poor. PET is the modality of choice for disease staging. Testing tumours for c-Kit mutations may allow selected patients to participate in trials of tyrosine kinase inhibitors.
Subject(s)
Anal Canal/surgery , Antineoplastic Agents/therapeutic use , Anus Neoplasms/therapy , Digestive System Surgical Procedures , Imatinib Mesylate/therapeutic use , Melanoma/therapy , Adult , Aged , Aged, 80 and over , Anal Canal/pathology , Anus Neoplasms/genetics , Anus Neoplasms/mortality , Anus Neoplasms/pathology , Dacarbazine/therapeutic use , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Male , Melanoma/genetics , Melanoma/mortality , Melanoma/pathology , Middle Aged , Mutation , Neoplasm Staging , Niacinamide/analogs & derivatives , Niacinamide/therapeutic use , Phenylurea Compounds/therapeutic use , Proto-Oncogene Proteins c-kit/genetics , Retrospective Studies , Sorafenib , Survival RateABSTRACT
BACKGROUND: Melanoma of the anorectal mucosa is a rare but highly aggressive tumor. Its presenting symptoms are frequently confused with hemorrhoids, thereby causing a delay in diagnosis. Anorectal melanoma carries with it a very poor prognosis. There is a paucity of data investigating management options for anorectal melanoma, and even fewer data reporting recurrent or refractory cases. CASE PRESENTATION: This case documents a 41-year-old female with a long history of hemorrhoids presenting with anorectal discharge. She was incidentally found have anorectal melanoma following surgical resection. Systemic diagnostic work-up demonstrated PET-avid lymphadenopathy in her right groin. She underwent right groin dissection. However, seven months later she recurred in her right groin and a new recurrent mass was found in her pelvis. She underwent a second groin dissection and resection of the pelvic recurrence. This was followed by a course of hypofractionated radiation therapy then systemic immunotherapy. DISCUSSION: Surgery has been the mainstay of treatment. However, the extent of surgery has been the topic of investigation. Historically, radical resections have been performed but they result in high rates of post-operative morbidity. Newer studies have compared radical resection with wide local excisions and found comparable outcomes. Anorectal melanoma is frequently a systemic disease. The ideal systemic therapy regimen has not yet been determined but numerous studies show a benefit to multi-agent treatments. Radiation therapy is typically given in the post-operative or palliative setting. CONCLUSIONS: Anorectal mucosal melanoma is a very rare but aggressive disease with a poor prognosis. The overall treatment goal should strive to optimize quality of life and tumor control while minimizing treatment-related morbidities.
ABSTRACT
OBJECTIVES: To review the fetal and maternal outcomes of women with a diagnosis of gastrointestinal (GI) cancer before or during pregnancy. METHODS: We conducted a retrospective cohort study of pregnant women referred to a single tertiary care centre with a current or previous diagnosis of GI malignancy. Maternal, obstetric, and infant data were recorded. RESULTS: We identified 18 pregnancies in 13 women. Nine women were found to have a GI malignancy during pregnancy (group 1). There was an indirect maternal death in this group in a woman with advanced gastric adenocarcinoma. Nine unique pregnancies occurred in eight women with diagnosis and management of GI malignancies before their pregnancies (group 2). CONCLUSION: GI malignancies are difficult to diagnose and manage during pregnancy and are usually advanced at the time of diagnosis. Surgery can be performed during pregnancy if necessary, with chemotherapy and radiotherapy usually deferred to the postpartum period. Women who have had a prior GI malignancy have special circumstances related to the type of surgery performed and previous exposure to chemotherapy. These patients may benefit from a multidisciplinary team effort to optimize their care.
Objectifs : Analyser les issues fÅtales et maternelles des femmes ayant reçu un diagnostic de cancer gastro-intestinal (GI) avant ou pendant la grossesse. Méthodes : Nous avons mené une étude de cohorte rétrospective portant sur des femmes enceintes orientées vers un seul centre de soins tertiaire en raison d'un diagnostic actuel ou précédent de tumeur maligne GI. Les données maternelles, obstétricales et infantiles ont été consignées. Résultats : Nous avons identifié 18 grossesses chez 13 femmes. Une tumeur maligne GI a été constatée chez neuf de ces femmes pendant la grossesse (groupe 1). Un décès maternel indirect a été signalé dans ce groupe chez une femme présentant un adénocarcinome gastrique avancé. Neuf grossesses uniques ont été constatées chez huit femmes ayant obtenu un diagnostic de tumeur maligne GI et ayant fait l'objet d'une prise en charge avant la grossesse (groupe 2). Conclusion : Les tumeurs malignes GI sont difficiles à diagnostiquer et à prendre en charge pendant la grossesse, et se trouvent habituellement à un stade avancé au moment du diagnostic. Une chirurgie peut être menée pendant la grossesse, au besoin, les traitements de chimiothérapie et de radiothérapie étant habituellement reportés à la période postpartum. Les femmes ayant déjà présenté une tumeur maligne GI comptent des circonstances particulières liées au type de la chirurgie dont elles ont fait l'objet et à leur exposition précédente à la chimiothérapie. Ces patientes pourraient tirer avantage d'une approche d'équipe multidisciplinaire pour optimiser les soins qu'elles reçoivent.
Subject(s)
Gastrointestinal Neoplasms/complications , Pregnancy Complications, Neoplastic , Pregnancy Outcome , Adenocarcinoma/complications , Adolescent , Adult , Antineoplastic Agents/therapeutic use , Birth Weight , Cesarean Section , Cohort Studies , Fatal Outcome , Female , Gastrointestinal Neoplasms/diagnosis , Gastrointestinal Neoplasms/therapy , Gestational Age , Humans , Intensive Care, Neonatal , Postpartum Period , Pregnancy , Pregnancy Complications, Neoplastic/drug therapy , Pregnancy Complications, Neoplastic/surgery , Premature Birth/epidemiology , Retrospective Studies , Stomach Neoplasms , Tertiary Care Centers , Young AdultABSTRACT
Tumors of the anus and perianal skin are rare. Their presentation can vary and often mimics common benign anal pathology, thereby delaying diagnosis and appropriate and timely treatment. The anatomy of this region is complex because it represents the progressive transition from the digestive system to the skin with many different co-existing types of cells and tissues. Squamous cell carcinoma of the anal canal is the most frequent tumor found in the anal and perianal region. Less-frequent lesions include Bowen's and Paget's disease, basal cell carcinoma, melanoma, and adenocarcinoma. This article aims to review the clinical presentation, diagnostic evaluation, and treatment options for neoplasms of the anal canal and perianal skin.
ABSTRACT
This article is one case report of 49 year-old woman diagnosed with malignant melanoma of the anal canal. The tumor was detected at early stage and initially treated with local excision, followed by adjuvant interstitial brachytherapy. Since the patient complained of painful local ulceration and atypical cells were found at biopsy, abdominoperineal resection of the rectum was performed and a sterile specimen was obtained, proving the efficacy of adjuvant brachytherapy for local control. Patient is now considered disease free for 30 months after primary treatment.